SCHEMBL30725909

SCHEMBL30725909

CC(=O)N1c2ccccc2[S+]([O-])c2ccc(C(F)(F)F)cc21

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ P2RX4 Q99571 1/20 0.43
▸ HSD17B3 P37058 1/20 0.41
▸ NOTUM Q6P988 1/20 0.39
▸ GAA P10253 3/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ NOX1 Q9Y5S8 1/20 0.38
▸ NPSR1 Q6W5P4 2/20 0.37
▸ MAPT P10636 1/20 0.37
▸ HPGD P15428 2/20 0.36
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ HTT P42858 1/20 0.35
▸ LMNA P02545 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ CES2 O00748 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ SNCA P37840 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24439580 1.00 P2RX4 (0.43) P2RX4HSD17B3NOTUMGAASMN1; SMN2
SCHEMBL30725915 0.80 NOX1 (0.43) NOTUMGAASMN1; SMN2NOX1NPSR1
SCHEMBL24439313 0.80 HSD17B3 (0.41) HSD17B3NOTUMGAASMN1; SMN2NOX1
SCHEMBL24439324 0.80 NOX1 (0.43) NOTUMGAASMN1; SMN2NOX1NPSR1
SCHEMBL24439587 0.77 SNCA (0.43) HSD17B3NOTUMGAASMN1; SMN2NOX1
SCHEMBL11374002 0.76 NR1I3 (0.42) GAANPSR1HPGDMEN1KMT2A
SCHEMBL11376963 0.74 TBXAS1 (0.41) SMN1; SMN2MEN1KMT2AHTTLMNA
SCHEMBL24439579 0.73 NOX1 (0.67) HSD17B3GAANOX1NPSR1HPGD
SCHEMBL11372413 0.73 NOS1 (0.41) MEN1KMT2ALMNAKDM4EL3MBTL1
SCHEMBL24439577 0.69 NOTUM (0.33) NOTUMGAASMN1; SMN2NOX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025868-A1 PHENOTHIAZINE COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AGE-RELATED AND NEUROLOGICAL DISEASES ICAHN SCHOOL MED MOUNT SINAI (US) 2024-01-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025868-A1 PHENOTHIAZINE COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AGE-RELATED AND NEUROLOGICAL DISEASES ACE2, BACE2, PSEN2 P2RX4 2641/4885HSD17B3 2752/4885NOTUM 1739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback